Alzheimer’s Care Is Entering a New Era
New FDA-approved therapies like Leqembi, Donanemab, and Aduhelm now offer patients a real opportunity to slow decline—but only if diagnosis happens early.
35% slower decline
with Donanemab in early-stage patients (JAMA, 2023)
27% slower decline
with Leqembi vs. placebo (NEJM, 2022)
This makes early detection not just helpful—but essential.
THE PROBLEM
Most Patients Go Undiagnosed
Just 8–10% of patients over 65 are screened for cognitive impairment
PCPs recognize fewer than 1 in 10 MCI cases (New Hampshire Bulletin, 2024)
9 out of 10 adults with measurable impairment never receive a diagnosis (PMC, 2022)
Primary Care isn't set up for this
Time
Most tools require 15–30 minutes
Workflow
Tablets, logins, and scoring create barriers
Billing
Teams often lack clarity on what’s reimbursable
What We Provide
A dedicated care manager handles ongoing patient check-ins, care plan updates, and resource navigation
Services aligned with CMS-reimbursed Chronic Care Management (99490 / 99487 / 99491)
We coordinate across specialties, caregivers, and support services
All notes and care coordination updates are automatically shared with your EHR team or faxed summaries—so you stay informed but unburdened
CaringAI supports fully reimbursable care:
96116 / 96132
Cognitive evaluation & interpretation
99483
Alzheimer’s-focused care planning
99490 / 99487 / 99491
Chronic Care Management
With Caring AI Listen + Plan + optional CCM services, you can:
Identify eligible patients with no added visit burden
Auto-generate documentation for billing
Improve quality of care while unlocking new revenue
Ideal For:
Annual Wellness cognitive screening
Pre-visit outreach or post-discharge follow-up
Chronic care workflows (especially dementia + comorbidity)
Closing care gaps in aging populations